| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
|
Medicine details |
|
| Medicine name | denosumab (Xgeva®) |
| Formulation | 120 mg solution for injection |
| Reference number | 1008 |
| Indication | Prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours |
| Company | Amgen Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/06/2011 |
| NICE guidance | |